Supply Chain

Limitations of the Drug Supply Chain Security Act for pharma-and three strategies to fix them.

The recent formation of three mega supply-chain purchasing groups (Walgreen’s-AllianceBoots-AmerisourceBergen-Rite-Aid, McKesson-Celesio, CVS-Cardinal) denotes a shift in the balance of power between wholesalers, chains, generic pharmaceutical companies and branded pharma companies.

An advocate of business system automation in the global pharma supply chain offers a six-pronged approach to adapting to the realities of a new age of mounting regulation and customer expectations.

A Pharm Exec conversation with AmerisourceBergen CEO Steve Collis

Leaders should understand the key themes of risk intelligence in the supply chain, writes Bronwyn Kunhardt.

Kathleen Iacocca and Yao Zhao discuss why direct supply chain models can be more sustainable than resell models in the long run and whether they can be implemented in the US.

New legislation and changes in policy at FDA are leading to better control of the API supply chain.

Examining a new three-part formula to enable the supply chain function to manage market pressures while delivering on the bottom line.

As insurers, payers, and drug plan operators eye increased generic drug use as key to cutting healthcare costs, pharma companies are ramping up efforts to delay marketing of copycat products.

Customer-focused supply-chain capabilities are becoming a more important part of a company's competitive advantage.

After years of asking questions, the National Highway Traffic Safety Administration (NHTSA)is moving closer to a protocol "for assessing the driving-impairment risks of drugs". Ben Comer reports.

New research sheds fresh light on a trend with serious consequences for the public health-not only in the United States but for patients worldwide.

The problem of supply-chain security has taken center stage with a number of recent initiatives, writes Patricia Van Arnum.